Le Lézard
Classified in: Health
Subjects: POL, AVO

CSPI Urges Administration not to Appoint Dr. Robert Redfield, with History of Scientific Misconduct, as CDC Director


WASHINGTON, March 21, 2018 /PRNewswire-USNewswire/ -- Statement of CSPI President Dr. Peter Lurie

President Trump is reportedly likely to nominate Robert Redfield of the University of Maryland to be director of the Centers for Disease Control and Prevention.  This appointment would be disastrous for at least three reasons.  First, he has no experience running a public health agency, and does not have the all-important relationships with state and local public health officials such experience would bring.  Second, based on work I conducted with Sidney Wolfe at Public Citizen in the mid-1990s, he has been credibly accused of scientific misconduct for exaggerating the benefits of a putative HIV vaccine, for which he was investigated by the military.  Third, he has supported a variety of policies related to HIV/AIDS that are anathema to the great majority of public health professionals: mandatory HIV testing, reporting of positive HIV results to public health authorities without the patient's consent, and quarantining of HIV-positive individuals in the military.

What one wants in a director of the Centers for Disease Control and Prevention is a scientist of impeccable scientific integrity.  What one would get in Robert Redfield is a sloppy scientist with a long history of scientific misconduct and an extreme religious agenda.  We urge the administration not to appoint Dr. Redfield.

 

SOURCE Center for Science in the Public Interest


These press releases may also interest you

at 07:40
The "Global Weight Loss Drugs Market: Analysis By Product Type, By Drug Type, By Distribution Channel, By End User, By Region, Size and Trends with Impact of COVID-19 and Forecast up to 2029" report has been added to ResearchAndMarkets.com's...

at 07:35
Arrowhead Pharmaceuticals, Inc. today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company's proprietary Targeted RNAi Molecule...

at 07:35
Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an Unfavorable Impact of $0.08 Per Share Related to Acquired IPR&D and...

at 07:30
During an awards ceremony to present the 2024 list of Best Workplacestm in Canada, Great Place to Work® announced the 50 Best Workplacestm in Canada with 100-999 employees....

at 07:05
At the ESCMID Global 2024 conference, Bruker is enhancing its innovative diagnostic solutions in microbial identification, antimicrobial susceptibility testing (AST), early sepsis diagnostics, and other infectious disease assays. Simplifying...

at 07:00
Bristol Myers Squibb today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo® (nivolumab) in combination with cisplatin and gemcitabine for the...



News published on and distributed by: